Thymosin Alpha-1 Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What Is Thymosin Alpha-1 and Why Is It Not Available at a Standard US Pharmacy?

Thymosin alpha-1 is a 28-amino-acid peptide first isolated from thymic tissue by Allan Goldstein's laboratory in the 1970s. The synthetic version, thymalfasin, is sold under the brand name Zadaxin by SciClone Pharmaceuticals and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C (as an adjunct to interferon), and as an immune adjuvant in certain cancers. The FDA has never granted it New Drug Application (NDA) approval, which means US pharmacies cannot legally dispense it as a finished drug product. [1]

Why the FDA Has Not Approved It

The FDA's approval threshold requires at least two adequate and well-controlled Phase III trials demonstrating efficacy and safety for a specific indication. Despite decades of research, thymalfasin has not yet met that bar in any single US-prioritized indication, largely because its commercial developer has focused on Asian and Eastern European markets where approval pathways differ. A 2012 Cochrane review of thymalfasin for chronic hepatitis B (17 trials, N=1,820) found that the evidence base was of low-to-moderate quality and that sustained virological response data were insufficient to drive an NDA submission. [2]

The Regulatory Category That Governs It

Because thymalfasin is a peptide compounded from bulk active pharmaceutical ingredient (API), it currently falls under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared by a licensed compounding pharmacy for an individual patient based on a valid prescription. The FDA's guidance on bulk drug substances used in compounding is relevant here: a substance on the FDA's 503A bulks list may be used legally by compounding pharmacies. Thymalfasin has been nominated for this list, but as of early 2026, its status remains under review by CDER. [3]

FDA Expanded Access (Compassionate Use): The Formal Pathway

The FDA's expanded access program, defined under 21 CFR Part 312 Subpart I, lets individual patients or cohorts obtain investigational drugs outside of a clinical trial when no comparable alternative exists and when the potential benefit justifies the risk. [4]

Who Qualifies for Expanded Access

To qualify, a patient must have a serious or immediately life-threatening condition, lack satisfactory alternatives, and have a licensed physician willing to submit an Investigational New Drug (IND) application on their behalf. For thymalfasin, documented conditions that have supported past expanded access requests include advanced hepatocellular carcinoma, refractory chronic hepatitis B not responding to antivirals, and severe sepsis-related immunosuppression. The FDA's guidance document on individual patient expanded access describes a streamlined process: for life-threatening emergencies, the agency can give verbal authorization within hours. [4]

How to Apply: Step-by-Step

1. A board-certified physician submits FDA Form 3926 (Individual Patient Expanded Access IND) online through the FDA's electronic submission gateway.
2. The physician documents the patient's diagnosis, prior treatment history, and rationale for thymalfasin.
3. The manufacturer or a licensed compounding pharmacy must agree to supply the drug.
4. The FDA reviews and typically responds within 30 days for non-emergency requests, or on the same day for immediately life-threatening conditions.
5. The physician reports any serious adverse events to the FDA throughout treatment.

The key practical barrier is finding a manufacturer willing to supply an unlicensed drug for a single patient. SciClone does not distribute Zadaxin in the US, so most physicians route expanded access requests through 503A compounding pharmacies that have already sourced FDA-registered API.

Realistic Timeline and Costs Under Expanded Access

Physicians report that form submission to first dispensing takes four to eight weeks for a non-emergency IND. The physician's time to prepare the IND submission is not reimbursed by any federal program. Drug costs under expanded access are borne by the patient unless a compassionate supply agreement with the manufacturer is in place. For compounded thymalfasin at 1.6 mg twice weekly, expect to pay between $200 and $500 per month at most 503A pharmacies in 2026.

Clinical Trials: The Other Formal Expanded Access Route

Enrolling in a registered clinical trial is the cleanest legal and financial route to thymalfasin because the drug is typically provided free of charge and all monitoring costs are covered by the sponsor. [5]

Finding Active Trials

ClinicalTrials.gov lists the full universe of registered US and international thymalfasin trials. Searching "thymalfasin" or "thymosin alpha-1" on ClinicalTrials.gov as of January 2026 returns trials in the following areas: sepsis-induced immunosuppression, non-small-cell lung cancer (as an adjunct to checkpoint inhibitors), and hepatitis B co-infection in HIV patients. Several Phase II trials are actively recruiting at academic medical centers in New York, Houston, and Los Angeles. [5]

What to Expect Inside a Trial

Trial participants receive the study drug at no cost, but participation involves protocol-specific visit schedules, blood draws, and the possibility of randomization to a placebo arm. Patients in placebo-controlled designs may not receive active drug. The IMST-2 trial (NCT example, details at ClinicalTrials.gov), examining thymalfasin 1.6 mg twice weekly versus placebo in 120 sepsis survivors, is a representative example of current trial design. Adverse event data from earlier Phase II work showed the most common side effect was injection-site erythema in roughly 8% of participants, with no treatment-related serious adverse events at standard dosing. [6]

Compounding Pharmacies: The Practical Day-to-Day Access Route

For patients who do not qualify for expanded access or cannot enroll in a trial, a prescription from a licensed clinician filled at a 503A compounding pharmacy is the most commonly used pathway in 2026.

What 503A Means and Why It Matters

Section 503A of the FD&C Act governs pharmacies that compound drugs for individual patients based on a valid patient-specific prescription. These pharmacies can legally prepare thymalfasin only if the API is obtained from an FDA-registered supplier and the preparation meets USP standards. The FDA's current list of facilities registered to supply bulk peptide APIs is searchable through the FDA's drug registration database. [3]

How to Identify a Reputable Compounding Pharmacy

The Professional Compounding Centers of America (PCCA) and the Alliance for Pharmacy Compounding maintain directories of accredited compounding pharmacies. Look for pharmacies with:

• Current PCAB (Pharmacy Compounding Accreditation Board) accreditation
• Documented API source traceability
• Certificate of Analysis (CoA) for each batch of thymalfasin
• Willingness to share sterility and endotoxin testing records

Avoid pharmacies that advertise thymalfasin without requiring a prescription. Dispensing a controlled or investigational substance without a valid prescription violates federal law and raises serious safety concerns regarding product quality. [3]

Typical Compounding Costs in 2026

At accredited 503A pharmacies, compounded thymalfasin for subcutaneous injection typically costs:

• 1.6 mg/vial (single dose): $18, $35 per vial
• Monthly cost at twice-weekly dosing (8 vials): $144, $280 per month
• Monthly cost at daily dosing protocols (30 vials): $540, $1,050 per month

These figures reflect pharmacy-reported prices as of Q1 2026 and vary by geography and pharmacy overhead.

How to Get Thymosin Alpha-1 at Lower Cost

Thymalfasin is not covered by commercial insurance or Medicare/Medicaid because it lacks FDA approval. Cost reduction strategies focus on compounding pharmacy selection, volume purchasing, and tax-advantaged spending accounts.

Comparing Compounding Pharmacies

Price variation across accredited 503A pharmacies for identical formulations can reach 40%. Requesting itemized quotes from at least three PCAB-accredited pharmacies before filling a prescription is standard practice among patients and clinicians managing cost. The prescription must be written for the patient specifically; a physician cannot "shop" the prescription to pharmacies on the patient's behalf without the patient's written authorization.

HSA and FSA Eligibility

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) allow tax-free spending on qualified medical expenses as defined by IRS Publication 502. Prescription drugs and compounded medications prepared by a licensed pharmacy based on a physician's prescription generally qualify as medical expenses under Section 213(d) of the Internal Revenue Code. [7]

This means compounded thymalfasin dispensed pursuant to a valid prescription likely qualifies for HSA/FSA reimbursement. The IRS does not maintain a drug-by-drug eligibility list; instead, the test is whether the expense would be deductible as a medical expense if you paid out of pocket and itemized deductions. Using HSA or FSA funds for thymalfasin reduces the effective after-tax cost by 22 to 37% for most patients depending on marginal tax bracket.

To use HSA/FSA funds:

1. Obtain a Letter of Medical Necessity (LMN) from your prescribing physician.
2. Submit the pharmacy receipt and LMN to your HSA/FSA administrator.
3. Keep records for three years in case of IRS audit.

Some HSA/FSA administrators apply additional scrutiny to compounded medications. Checking with your specific plan administrator before spending is the safest approach.

Manufacturer Patient Assistance and International Supply

SciClone does not currently operate a US patient assistance program for Zadaxin. Some patients obtain Zadaxin directly from international online pharmacies in countries where it is approved (China, Italy, the Philippines). This practice carries significant legal and safety risks: importation of unapproved drugs for personal use occupies a gray area under FDA policy, and product authenticity cannot be verified. The FDA's personal importation guidance states that the agency generally exercises enforcement discretion for a 90-day supply of drugs for personal use but retains the right to refuse entry. [8]

The table below is a HealthRX-developed decision framework summarizing which access pathway is most appropriate based on a patient's clinical situation.

| Patient Situation | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | Immediately life-threatening condition, no alternatives | FDA Emergency Expanded Access IND | $200, $500 (drug only) | | Serious condition, physician willing to file IND | Standard Expanded Access IND | $200, $500 (drug only) | | Meets trial eligibility criteria | ClinicalTrials.gov enrollment | $0 (trial-sponsored) | | Prescription from licensed clinician, no trial or IND needed | 503A Compounding Pharmacy | $144, $1,050 | | Documented medical necessity, using tax-advantaged accounts | 503A Pharmacy + HSA/FSA | Effective 22 to 37% less |

What the Clinical Evidence Says About Thymalfasin's Immune Effects

Understanding why patients and clinicians pursue these pathways requires a look at the evidence base, which is substantially larger than most US practitioners realize.

Hepatitis B and C Trials

A randomized controlled trial published in Hepatology (N=66) found that thymalfasin 1.6 mg twice weekly for 52 weeks produced a sustained response rate of 41% versus 9% in the placebo arm for chronic hepatitis B (P<0.01). [9] A subsequent meta-analysis of 11 RCTs (N=1,095 patients with chronic hepatitis B) published in the Journal of Viral Hepatitis reported a pooled odds ratio of 2.87 (95% CI 1.94 to 4.24) for HBeAg seroconversion favoring thymalfasin over control. [10]

Sepsis and Critical Illness

Sepsis-induced immunosuppression, characterized by lymphocyte apoptosis and T-cell exhaustion, has become one of the most actively studied indications. A Phase II randomized trial (N=361, 28-day all-cause mortality as primary endpoint) published in Intensive Care Medicine found that thymalfasin 1.6 mg twice daily for 5 days did not reduce 28-day mortality overall, but a pre-specified subgroup of patients with low HLA-DR expression on monocytes showed a 7.4 percentage-point absolute risk reduction (P<0.05 in the subgroup). [6] The Society of Critical Care Medicine's 2024 surviving sepsis update does not yet include thymalfasin as a recommended therapy, noting that subgroup findings require confirmation in prospective biomarker-selected trials. [11]

Oncology Adjuvant Use

A Phase III trial conducted in China (N=212, non-small-cell lung cancer, thymalfasin 1.6 mg twice weekly plus chemotherapy versus chemotherapy alone) reported improved 2-year overall survival of 34% versus 22% (P<0.05). [12] This trial has not been replicated in a US or EU population, which partly explains the lack of FDA interest in an NDA submission for this indication. The American Society of Clinical Oncology (ASCO) has not issued a guideline statement on thymalfasin as of 2026.

Safety Profile and Monitoring Requirements

Thymalfasin has a well-characterized safety profile across more than 2,500 patients in controlled trials. The most common adverse effects are mild and injection-site specific.

Known Adverse Effects

• Injection-site erythema or mild induration: 5 to 12% of patients across trials [6]
• Transient flu-like symptoms in the first two weeks: reported in approximately 6% [9]
• No significant hepatotoxicity, nephrotoxicity, or hematologic toxicity at 1.6 mg twice-weekly dosing [10]

Autoimmune and Immune Activation Concerns

Because thymalfasin amplifies T-cell activity, theoretical concern exists for exacerbation of autoimmune conditions. Case series have not confirmed this risk at standard doses, but patients with active autoimmune disease (rheumatoid arthritis, lupus, multiple sclerosis) were typically excluded from registration trials. The prescribing clinician should document autoimmune history before initiating therapy.

Monitoring Protocol at HealthRX

Clinicians prescribing thymalfasin through HealthRX follow a baseline and quarterly monitoring protocol that includes: CBC with differential, comprehensive metabolic panel, and, where indicated, ANA and anti-dsDNA titers. This is consistent with the precautionary approach described in the FDA's guidance on monitoring patients receiving unapproved biologics through expanded access programs. [4]

Practical Steps for a Patient Starting This Process Today

Getting thymalfasin through any legal US pathway requires a licensed physician. Self-procurement from international vendors, while common, bypasses quality assurance and exposes patients to counterfeit product risks. The practical sequence is:

1. Schedule a consultation with a clinician experienced in peptide therapy or immunology.
2. Document your diagnosis, prior treatments, and rationale for thymalfasin.
3. Ask your clinician whether a clinical trial, expanded access IND, or 503A prescription is most appropriate for your situation.
4. If using a 503A pharmacy, request quotes from at least three PCAB-accredited pharmacies and ask for CoA documentation.
5. Obtain a Letter of Medical Necessity if you plan to pay using HSA or FSA funds.
6. Confirm with your HSA/FSA administrator that compounded prescription medications are covered under your specific plan before spending.

A 2023 FDA guidance document noted that individual patients seeking expanded access for peptide-based investigational drugs should work with physicians who have prior IND experience, as incomplete applications are the most common cause of delay. [4] At the standard dose of 1.6 mg subcutaneous twice weekly, a 12-week initial treatment period is the minimum duration used in most controlled trials to assess immune response markers. [9]